Overview

Teclistamab in Previously Treated AL Amyloidosis

Status:
RECRUITING

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This is a phase II study in patients with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab

Phase:

PHASE2

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Focal Adhesion Protein-Tyrosine Kinases